Follistatin-344 vs GHK-Cu
Updated July 27, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Follistatin-344 and GHK-Cu (also searched as GHK-Cu vs Follistatin-344) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Follistatin-344 centers on muscle, while GHK-Cu leans toward skin. On indexed research, GHK-Cu is ahead (Follistatin-344: 5 studies, Human evidence; GHK-Cu: 6, Preclinical). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Follistatin-344 is strongest for muscle; GHK-Cu for skin.
- •Evidence: Follistatin-344 Human evidence (5 studies) vs GHK-Cu Preclinical (6).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
Myostatin inhibition | Muscle growth
Copper Peptide | Skin Regeneration & Anti-Aging Compound
Follistatin-344 vs GHK-Cu: side-by-side
| Metric | Follistatin-344 | GHK-Cu |
|---|---|---|
| Class | Muscle | Skin |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Human evidence | Preclinical |
| Studies indexed | 5 | 6 |
| Research level | Limited Research | Well Studied |
| Strongest effect | Muscle & body comp | Skin & aesthetics |
| Healing & recovery | 1.0 | 4.0▲ |
| Muscle & body comp | 5.0▲ | 1.0 |
| Metabolic & appetite | 2.0 | 3.0▲ |
| Neuro & mood | 1.0 | 2.0▲ |
| Sleep & circadian | 0.0 | 1.0▲ |
| Inflammation & immune | 1.0 | 4.0▲ |
| Skin & aesthetics | 2.0 | 5.0▲ |
▲ marks the higher AI-assigned effect score (0–5, describing where the literature concentrates — not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Follistatin-344 | GHK-Cu |
|---|---|---|
| Mechanism | Myostatin inhibitor | Copper-binding tripeptide (GHK-Cu); tissue-remodeling / regenerative signaling |
| Route | — | Topical / subcutaneous |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Follistatin-344?
### Follistatin-344 Summary Follistatin-344 is a glycoprotein that plays a crucial role in the regulation of muscle growth and development by inhibiting myostatin, a negative regulator of muscle mass. Its potential therapeutic applications are being explored in various fields, including muscle wasting disorders and regenerative medicine.
Full Follistatin-344 profile, mechanism & studies →What is GHK-Cu?
Copper-binding tripeptide widely used in skin, hair, and wound-healing contexts, with systemic effects explored in research.
Full GHK-Cu profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | GHK-Cu | 4.0/5 effect signal |
| Muscle | Follistatin-344 | 5.0/5 effect signal |
| Metabolic | GHK-Cu | 3.0/5 effect signal |
| Neuro | GHK-Cu | 2.0/5 effect signal |
| Sleep | GHK-Cu | 1.0/5 effect signal |
| Inflammation | GHK-Cu | 4.0/5 effect signal |
| Skin | GHK-Cu | 5.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Follistatin-344 and GHK-Cu?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Follistatin-344 vs GHK-Cu: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Follistatin-344 has 5 approved studies indexed (Human evidence), and GHK-Cu has 6 (Preclinical). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Follistatin-344 or GHK-Cu better?
It depends on your goal. Follistatin-344 is strongest for muscle; GHK-Cu for skin. GHK-Cu has more indexed studies (6). See the goal-by-goal breakdown above.
Is Follistatin-344 or GHK-Cu better for weight loss?
GHK-Cu shows the stronger metabolic & appetite profile (3.0/5) in the AI-assigned effect profile — though weight-loss outcomes depend on the individual and the evidence base.
Is Follistatin-344 or GHK-Cu better for muscle?
Follistatin-344 leads on the muscle & body-composition axis (5.0/5).
Which has more research, Follistatin-344 or GHK-Cu?
Follistatin-344 has 5 approved studies indexed (Human evidence); GHK-Cu has 6 (Preclinical). Higher counts mean more to read, not proven superiority.
Can you stack Follistatin-344 and GHK-Cu?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Follistatin-344 vs GHK-Cu?
Follistatin-344: no community-reported effects logged yet. GHK-Cu: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Follistatin-344 or GHK-Cu FDA-approved?
Follistatin-344 is a research-use compound and is not FDA-approved. GHK-Cu is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is GHK-Cu better than Follistatin-344?
For skin, GHK-Cu has the edge; for muscle, Follistatin-344 does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Follistatin-344 and GHK-Cu are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 27, 2026.